Sanofi: EU approval recommended for subcutaneous Sarclisa

The Committee for Medicinal Products for Human Use (CHMP) has recommended approval of the new subcutaneous formulation of Sarclisa for the treatment of multiple myeloma in the EU. This recommendation is based on study results showing efficacy similar to that of traditional intravenous infusion.

If approved, this formulation, administered via a portable injector, would be the first cancer treatment of its kind available in Europe. Sanofi highlights the potential improvement in patient experience offered by this innovative delivery method.

Phase III trials have demonstrated that the use of Sarclisa SC with a portable injector improves patient satisfaction compared to the intravenous method, promising an advance in the comfort and flexibility of available treatments.